This inventor holds 2 USPTO granted patents. Top assignee: Case Western Reserve University. Active years: 2022-2025.
Company Filing History:
Years Active: 2022-2025
Title: German Corredor: Innovator in Cancer Research
Introduction
German Corredor is a prominent inventor based in Bogotá, Colombia. He has made significant contributions to the field of cancer research, particularly in the area of tumor analysis and prediction of recurrence in lung cancer. His innovative work has led to the development of advanced methodologies that leverage technology to improve patient outcomes.
Latest Patents
German Corredor holds 2 patents related to his research. His latest patents include methods for phenotyping tumor infiltrating lymphocytes on hematoxylin and eosin (H and E) stained tissue images to predict recurrence in lung cancer. The first patent describes an apparatus that utilizes processors to analyze digitized images of tissue regions affected by disease. This apparatus computes contextual features and assigns cellular structures to clusters, ultimately generating predictions about the pathologic state of the disease. The second patent focuses on segmenting cellular nuclei in cancerous tissue images, classifying them as lymphocytes or non-lymphocytes, and utilizing machine learning classifiers to predict the likelihood of recurrence based on frequency distributions of clustered lymphocytes.
Career Highlights
German Corredor is affiliated with Case Western Reserve University, where he continues to advance his research in cancer pathology. His work is characterized by a strong emphasis on integrating technology with medical research to enhance diagnostic accuracy and treatment strategies.
Collaborations
He collaborates with notable colleagues such as Anant Madabhushi and Eduardo Romero, who share his commitment to improving cancer diagnostics and treatment through innovative research.
Conclusion
German Corredor's contributions to cancer research exemplify the impact of innovation in medical science. His patents and collaborative efforts are paving the way for advancements that could significantly improve patient care in oncology.